The phrase "a clinically favourable" is correct and usable in written English.
It can be used in medical or scientific contexts to describe a situation, condition, or outcome that is beneficial or positive from a clinical perspective.
Example: "The new treatment showed a clinically favourable response in the majority of patients."
Alternatives: "a clinically advantageous" or "a clinically positive".
The clinically favourable group associated with a low SQLE mRNA expression could be further divided by LIV-1 mRNA expression.
The clinically favourable group associated with a low SQLE mRNA expression could be further divided by mRNA expression levels of the oestrogen-regulated zinc transporter LIV-1.
Thus, the need for EGFR mutation testing among clinically favourable patients remains uncertain.
Here we hypothesise that the significantly higher CbG levels in clinically favourable NB tumours (Hettmer et al, 2003) may lead to reduced NB tumour aggressiveness.
We confirm that over one-third of patients have clinically favourable tumours without organ dysfunction despite widespread disease, and that for these patients careful observation is sufficient with a survival rate of 100%.
Microsatellite unstable tumours typically arise in the proximal colon, display mucinous histology, as well as lymphocytic infiltration, are clinically favourable compared with MSS tumours but respond poorly to 5-fluorouracil-based chemotherapy (Sinicrope and Sargent, 2012).
The average dose of fish oil administered in the current study (6.4 g/day or 0.09 g/kg/d) is consistent with the dose that Heller et al. [ 23] found to be clinically favourable (>0.1 g/kg/d).
For combined-marker analyses, patients were divided into three groups, based on expression of single markers, according to the following grouping: patients with only clinically favourable marker expression (group 1), patients with unfavourable marker expression of one or two of the three markers (group 2), and patients with only clinically unfavourable marker expression (group 3).
Importantly, these methylation-dependent subtypes stratify disease outcome; MSI tumours are clinically favourable, but respond poorly to 5-fluorouracil-based chemotherapy (Ribic et al, 2003; Carethers et al, 2004), whereas CIMP tumours have complex associations with patient outcome that may depend on MSI and/or BRAF V600E status (Kim et al, 2009; Ogino et al, 2009; Dahlin et al, 2010).
